MX366213B - Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma. - Google Patents

Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma.

Info

Publication number
MX366213B
MX366213B MX2012002221A MX2012002221A MX366213B MX 366213 B MX366213 B MX 366213B MX 2012002221 A MX2012002221 A MX 2012002221A MX 2012002221 A MX2012002221 A MX 2012002221A MX 366213 B MX366213 B MX 366213B
Authority
MX
Mexico
Prior art keywords
methyl
indol
propenamide
hydroxy
phenyl
Prior art date
Application number
MX2012002221A
Other languages
English (en)
Inventor
Slade Joel
John Parker David
S Bajwa Joginder
Acemoglu Murat
Original Assignee
Novartis Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366213(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag Star filed Critical Novartis Ag Star
Publication of MX366213B publication Critical patent/MX366213B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se preparan N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-iI)etil]amino] metil]fenil]-2E-2-propenamida y materiales de partida de la misma, sal de clorhidrato de éster metílico del ácido (E)-3-[4-[2-(2- metil-1H-indol-3-il)etilamino]metil]fenil)-acrílic o y 2-metil-triptamina, a través de métodos sintéticos nuevos.
MX2012002221A 2006-06-12 2007-06-07 Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma. MX366213B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30
PCT/US2007/070564 WO2007146718A2 (en) 2006-06-12 2007-06-07 Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino] methyl]phenyl]-2e-2-propenamide and starting materials therefor

Publications (1)

Publication Number Publication Date
MX366213B true MX366213B (es) 2019-07-01

Family

ID=38832681

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008015898A MX2008015898A (es) 2006-06-12 2007-06-07 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma.
MX2012002221A MX366213B (es) 2006-06-12 2007-06-07 Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008015898A MX2008015898A (es) 2006-06-12 2007-06-07 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma.

Country Status (32)

Country Link
US (2) US20090306405A1 (es)
EP (2) EP2394991B1 (es)
JP (2) JP5431926B2 (es)
KR (2) KR101493530B1 (es)
CN (4) CN102167678B (es)
AR (1) AR061296A1 (es)
AU (1) AU2007257883B2 (es)
BR (1) BRPI0712847A2 (es)
CA (1) CA2653657C (es)
CL (2) CL2007001691A1 (es)
DK (1) DK2032533T3 (es)
EC (1) ECSP088978A (es)
ES (2) ES2553255T3 (es)
GT (1) GT200800282A (es)
HK (2) HK1162029A1 (es)
HR (1) HRP20130798T1 (es)
IL (2) IL195211A (es)
IN (1) IN2015DN00910A (es)
JO (1) JO2900B1 (es)
MA (1) MA30513B1 (es)
MX (2) MX2008015898A (es)
MY (1) MY147576A (es)
NO (1) NO341870B1 (es)
NZ (1) NZ572707A (es)
PE (2) PE20120221A1 (es)
PL (1) PL2032533T3 (es)
PT (1) PT2032533E (es)
RU (1) RU2448090C2 (es)
TN (1) TNSN08507A1 (es)
TW (1) TWI395734B (es)
WO (1) WO2007146718A2 (es)
ZA (1) ZA200809490B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002237261A1 (en) 2001-01-09 2002-07-24 Novartis Pharma Gmbh Rapid method for screening compounds for in vivo activity
ES2280597T3 (es) 2001-11-06 2007-09-16 Novartis Ag Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de histona desacetilasa.
AU2007257882B2 (en) * 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Also Published As

Publication number Publication date
MX2008015898A (es) 2009-01-12
BRPI0712847A2 (pt) 2012-08-07
MA30513B1 (fr) 2009-06-01
ES2416286T3 (es) 2013-07-31
CA2653657A1 (en) 2007-12-21
JO2900B1 (en) 2015-09-15
RU2008151726A (ru) 2010-07-20
CN101466674A (zh) 2009-06-24
PE20080851A1 (es) 2008-08-18
CN102167678A (zh) 2011-08-31
EP2032533A2 (en) 2009-03-11
HK1162029A1 (en) 2012-08-17
TNSN08507A1 (en) 2010-04-14
EP2394991B1 (en) 2015-09-23
US8536346B2 (en) 2013-09-17
ZA200809490B (en) 2009-10-28
CN103086944A (zh) 2013-05-08
HRP20130798T1 (en) 2013-09-30
US20120010418A1 (en) 2012-01-12
NZ572707A (en) 2011-12-22
AU2007257883B2 (en) 2011-09-29
CA2653657C (en) 2015-10-27
JP2014058532A (ja) 2014-04-03
AR061296A1 (es) 2008-08-20
WO2007146718A2 (en) 2007-12-21
CL2010000973A1 (es) 2011-07-01
AU2007257883A1 (en) 2007-12-21
MY147576A (en) 2012-12-31
KR20140117703A (ko) 2014-10-07
WO2007146718A3 (en) 2008-06-19
JP5431926B2 (ja) 2014-03-05
TW200815345A (en) 2008-04-01
TWI395734B (zh) 2013-05-11
NO341870B1 (no) 2018-02-12
IL233836A0 (en) 2014-09-30
CN102174008A (zh) 2011-09-07
RU2448090C2 (ru) 2012-04-20
IL195211A (en) 2014-08-31
ECSP088978A (es) 2009-01-30
US20090306405A1 (en) 2009-12-10
KR20090015969A (ko) 2009-02-12
EP2394991A1 (en) 2011-12-14
IL195211A0 (en) 2009-08-03
CN102167678B (zh) 2013-08-28
PL2032533T3 (pl) 2013-08-30
IN2015DN00910A (es) 2015-07-10
CL2007001691A1 (es) 2008-05-16
EP2032533B8 (en) 2013-12-11
JP5809223B2 (ja) 2015-11-10
PE20120221A1 (es) 2012-03-21
PT2032533E (pt) 2013-06-28
ES2553255T3 (es) 2015-12-07
JP2009540008A (ja) 2009-11-19
KR101493530B1 (ko) 2015-02-13
HK1126759A1 (en) 2009-09-11
DK2032533T3 (da) 2013-07-01
EP2032533B1 (en) 2013-04-03
IL233836A (en) 2017-05-29
NO20090137L (no) 2009-03-03
KR101540194B1 (ko) 2015-07-28
GT200800282A (es) 2009-03-09

Similar Documents

Publication Publication Date Title
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
PH12012501725A1 (en) Polymorphs of n-hydroxy3-[4[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]2e-2-propenamide
TNSN08501A1 (en) Salts of n-hydroxy-3-[4-[[[2-(2- methyl-ih-indol-3-yl) ethyl ]amino]methyl ]phenyl ]-2e-2-propenamide
MX366213B (es) Procesamiento para hacer n-hidroxi-3 [4-[[[2-(2-metil-1h-indol-3-i l)etil]amino]metil]fenil] -2e-2-propenamida y materiales de partida para la misma.
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
ZA200809383B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
TH107690B (th) กระบวนการสำหรับการผลิตเกลือของ n-ไฮดรอกซี-3-[4-[[[2-(2-เมทธิล-1h-อินดอล-3-อิล)เอทธิล]อะมิโน]เมทธิล]ฟีนิล]-2e-2-โพรเพนเอไมด์